|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2013 | Professor Maurice Staquet, MD, MS (1930-2013) In Memoriam | Duez, Nicole; Eeckhoudt, Dominique; Kirkpatrick, Anne; Solbu, Gabriel; Suciu, Stefan; SYLVESTER, Richard; Van Glabbeke, Martine; BUYSE, Marc; Dalesio, Otilia; Renard, Josette; Rotmensz, Nicole | Journal Contribution | M |
| 2 | 2009 | Validation of prognostic indices using the frailty model | LEGRAND, Catherine; DUCHATEAU, Luc; JANSSEN, Paul; Ducrocq, V.; SYLVESTER, Richard | Journal Contribution | A1 |
| 3 | 2006 | Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trial | LEGRAND, Catherine; DUCHATEAU, Luc; SYLVESTER, Richard; JANSSEN, Paul; van der Hage, JA; van de Velde, CJH; Therasse, P | Journal Contribution | A1 |
| 4 | 2005 | A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model | LEGRAND, Catherine; Ducrocq, V; JANSSEN, Paul; SYLVESTER, Richard; DUCHATEAU, Luc | Journal Contribution | A1 |
| 5 | 2003 | Does it matter where you are treated? A treatment outcome study based on clinical trial data | LEGRAND, Catherine; DUCHATEAU, Luc; SYLVESTER, Richard; JANSSEN, Paul | Journal Contribution | M |
| 6 | 2003 | The side effects of Bacillus Calmette-Guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: results form a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial | SYLVESTER, Richard; van der Meijden, A.P.M.; Oosterlinck, W.; Hoeltl, W.; Bono, A. | Journal Contribution | A1 |
| 7 | 2002 | The shared frailty model and the power for heterogeneity tests in multicenter trials | DUCHATEAU, Luc; JANSSEN, Paul; LEGRAND, Catherine; LINDSEY, Patrick; NGUTI, Rosemary; SYLVESTER, Richard | Journal Contribution | A1 |
| 8 | 2002 | Multicollinearity in prognostic factor analysis using the EORTC QLQ-C30: identification and impact on model selection | VAN STEEN, Kristel; Curran, Desmond; Kramer, Jocelyn; MOLENBERGHS, Geert; Van Vreckem, Ann; SYLVESTER, Richard | Journal Contribution | A1 |
| 9 | 2002 | Variability in the recurrence rate of first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis or seven EORTC studies | Brausi, M.; Collette, L.; Kurth, K.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, W.A.; Newling, D.; Bouffioux, Christophe; SYLVESTER, Richard | Journal Contribution | A1 |
| 10 | 2002 | Analysing longitudinal continuous quality of life data with dropout | Curran, Desmond; MOLENBERGHS, Geert; Aaronson, N.; Fossa, S.; SYLVESTER, Richard | Journal Contribution | A1 |
| 11 | 2002 | Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials | SYLVESTER, Richard; van der Meijden, A.P.M.; Lamm, D.L. | Journal Contribution | A1 |
| 12 | 2002 | Treatment outcome studies: pitfalls in curent methods and practice | LEGRAND, Catherine; SYLVESTER, Richard; DUCHATEAU, Luc; JANSSEN, Paul; Therasse, Patrick | Journal Contribution | A1 |
| 13 | 1999 | Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: r=the final results of a European organization for research in cancer therapy genitourinary group trial | de Reijke, T.M.; Keuppens, F.I.; Whelan, P.; Kliment, J.; Robinson, M.R.G.; Rea, L.A.; SYLVESTER, Richard | Journal Contribution | |
| 14 | 1999 | Impact of the treating institution on survival of patients with "poor progosis" metastatic nonseminoma | Collette, L.; SYLVESTER, Richard; Stenning, S.P.; Fossa, S.D.; Mead, G.M.; de Wit, R.; de Mulder, P.H.M.; Neymark, N.; Lallemand, E.; Kaye, S.B. | Journal Contribution | |
| 15 | 1998 | Serum alpha-fetoprotein surge after the iniation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance | SYLVESTER, Richard; de Wit, R.; Collette, L.; de Mulder, P.H.M.; Sleijfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E.; Stoter, G. | Journal Contribution | |
| 16 | 1998 | Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study | Kaye, S.B.; Mead, G.M.; Fossa, S.; Cullen, M.; de Wit, R.; Bodrogi, I.; van Groeningen, C.; SYLVESTER, Richard; Collette, L.; Stenning, S.; de Prijck, L.; Lallemand, E. | Journal Contribution | |
| 17 | 1998 | Four cycles of BEP vs four cycles of VIR in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group | de Wit, R.; Stoter, G.; Sleijfer, D.T.H.; Neijt, J.P.; ten Bokkel Huinink, W.W.; de Prijck, L.; Collette, L.; SYLVESTER, Richard | Journal Contribution | |
| 18 | 1998 | Identifying the types of missingness in quality of life data from clinical trials | Curran, Desmond; Bacchi, M.; Hsu Schmitz, Shu-Fang; MOLENBERGHS, Geert; SYLVESTER, Richard | Journal Contribution | |
| 19 | 1997 | An introduction to the statistical design of phase III cancer clinical trials | SYLVESTER, Richard | Journal Contribution | |
| 20 | 1997 | Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone | Kurth, K.; Tunn, U.; Ay, R.; Schroder, F.; Pavone-Macaluso, M.; Debruyne, F.; ten Kate, F.; de Pauw, M.; SYLVESTER, Richard | Journal Contribution | |
| 21 | 1997 | Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European organization for research and treatment of cancer randomized phase III trial | Bartelink, H.; Rubens, R.D.; van der Schueren, E.; SYLVESTER, Richard | Journal Contribution | |
| 22 | 1997 | Analysis and presentation | Friberg, S.; Taube, A.; SYLVESTER, Richard; Oesterling, J.E. | Journal Contribution | |
| 23 | 1997 | Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/ European Organization for Research and Treatment of Cancer Trial | Horwich, A.; Sleijfer, D.T.; Fossa, S.D.; Kaye, S.B.; Oliver, R.T.D.; Cullen, M.H.; Mead, G.M.; de Wit, R.; de Mulder, P.H.M.; Dearnaley, D.P.; Cook, P.A.; Stenning, S.P.; SYLVESTER, Richard | Journal Contribution | |
| 24 | 1997 | Does isoniazed reduce side effects of intravesical Bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911 | Vegt, P.; van der Meijden, A.; SYLVESTER, Richard; Brausi, M.; Holtl, W.; de Balincourt, C. | Journal Contribution | |
| 25 | 1997 | Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group | de Wit, R.; Stoter, G.; Kaye, S.B.; Steijffer, D.Th.; Jones, W.G.; ten Bokkel Huinink, W.W.; Rea, L.A.; Collette, L.; SYLVESTER, Richard | Journal Contribution | |
| 26 | 1997 | Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminatomous testicular cancer | de Wit, R.; SYLVESTER, Richard; Tsitsa, C.; de Mulder, P.H.M.; Sleyfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E.; Stoter, G. | Journal Contribution | |
| 27 | 1996 | Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours | van der Meijden, A.P.M.; Hall, R.R.; Pavone Macaluso, M.; Pawinski, R.; SYLVESTER, Richard; van Glabbeke, M. | Journal Contribution | |
| 28 | 1996 | Phase II trails in Ta, T1 bladder cancer: the marker tumour concept | van der Meijden, A.P.M.; Hall, R.R.; Kurth, K.H.; Bouffioux, Ch.; SYLVESTER, Richard | Journal Contribution | |
| 29 | 1996 | Prognostic factors in metastatic prostate cancer | SYLVESTER, Richard | Journal Contribution | |
| 30 | 1996 | A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer | Pawinski, R.; SYLVESTER, Richard; Kurth, K.; Bouffioux, Christophe; van der Meijden, A.; Parmar, M.; BIJNENS, Luc | Journal Contribution | |
| 31 | 1996 | The role of biostatistics in cancer research | SYLVESTER, Richard | Journal Contribution | |
| 32 | 1996 | Can the forest plot be simplified without loosing relevant information in meta-analyses? | BIJNENS, Luc; SYLVESTER, Richard; Collette, L.; Ivanov, A.; Hoctin, Boes G. | Journal Contribution | |
| 33 | 1995 | EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma | de Mulder, P.H.M.; Oosterhof, G.O.N.; Bouffioux, Christophe; van Oosterom, A.T.; Vermeylen, K.; SYLVESTER, Richard | Journal Contribution | |
| 34 | 1994 | Surveillance of stage 1 non-seminomatous testicular cancer: a preliminary report of the EORTC GU-Cooperative Group Surveillance Study | van Oosterom, A.T.; Vendrik, G.; Keizer, J.; Droz, J.P.; Schornagel, J.; Croles, J.; Splinter, T.; ten Kate, F.; Vermeylen, K.; SYLVESTER, Richard | Journal Contribution | |
| 35 | 1991 | High-dose DTIC in advanced soft-tissue sarcomas in the adult | Buesa, J.M.; Mouridsen, H.T.; van Oosterom, A.T.; Verweij, J.; Wagener, T.; Steward, W.; Poveda, A.; Vestlev, P.M.; Thomas, D.; SYLVESTER, Richard | Journal Contribution | |
| 36 | 1991 | Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery | Jansen, R.L.H.; SYLVESTER, Richard; Sleyfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; Jones, W.G.; Keizer, J.; van Oosterom, A.T.; Meyer, S.; Vendrik, C.P.J.; de Pauw, M.; Stoter, G. | Journal Contribution | |
Loading...
5
0
5
0
false